SCHEMBL2690940

SCHEMBL2690940

C=CCCC(O)c1cccc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
ALDH1A1 P00352 2/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 2/20 0.41
ADRA2A P08913 2/20 0.39
ADRA2B P18089 2/20 0.39
ADRA2C P18825 2/20 0.39
ADRA1D P25100 2/20 0.39
ADRA1A P35348 2/20 0.39
ADRA1B P35368 2/20 0.39
SLC6A4 P31645 1/20 0.39
ACP3 P15309 3/20 0.38
KMT2A Q03164 3/20 0.38
HPGD P15428 2/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 1/20 0.37
METAP2 P50579 2/20 0.36
METAP1 P53582 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3239489 0.83 ALDH1A1 (0.46) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL15184721 0.83 ALDH1A1 (0.46) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL4949690 0.81 CYP2C9 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL15171136 0.77 ALDH1A1 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL3923362 0.77 CYP1A2 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL3923359 0.77 CYP1A2 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL8375544 0.77 CYP2C9 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL2734713 0.77 ALDH1A1 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL5384063 0.77 ALDH1A1 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL6313224 0.76 TSHR (0.46) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123253-A1 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2013-05-16 US disclosed
US-8168635-B2 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2012-05-01 US disclosed
US-20080261967-A1 Modulators of Central Nervous System Neurotransmitters HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-10-23 US disclosed
EP-1771435-A4 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS HUMAN BIOMOLECULAR RES INST (US) 2008-02-13 EP disclosed
EP-1771435-A2 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS Human Biomolecular Research Institute (US) 2007-04-11 EP disclosed
WO-2006025920-A2 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261967-A1 Modulators of Central Nervous System Neurotransmitters GAP43, SLC18A2, CHRNA6 CYP2C9 4487/4885CYP2C19 4423/4885ALDH1A1 2537/4885
US-20130123253-A1 MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS GAP43, SLC18A2, CHRNA6 CYP2C9 4487/4885CYP2C19 4423/4885ALDH1A1 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.